46 results
424B3
ATOS
Atossa Therapeutics Inc
7 Oct 13
Prospectus supplement
12:00am
commenced the voluntary recall of the ForeCYTE Breast Health Test Mammary Aspiration Specimen Cytology Test (MASCT). A copy of the press release … . held a conference call and discussed the voluntary recall. A script of that conference call is attached to this Report on Form 8-K as Exhibit 99.2
8-K
EX-99.2
ATOS
Atossa Therapeutics Inc
4 Oct 13
Other Events
12:00am
WHAINES:
Thanks. Good afternoon and thank you for joining today’s conference call to discuss the Company’s voluntary recall of its MASCT System. With us … today are Dr. Steven Quay, Chairman, CEO and President, and Kyle Guse, CFO. Today Atossa issued a press release announcing a voluntary recall
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
4 Oct 13
Other Events
12:00am
EXHIBIT 99.1
Medical Device Voluntary Recall - News Release
ForeCYTE Breast Health Test; Mammary Aspiration Specimen Cytology Test (MASCT …
www.nlrbh.com
On October 4, 2013Atossa Genetics Inc. (NASDAQ: ATOS) initiated a voluntary recall to remove the ForeCYTE Breast Health Test
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
27 Mar 14
Atossa Genetics Announces 2013 Financial Results
12:00am
by initiating studies using our medical devices as companion diagnostics.”
Recent Corporate Developments
Substantially completed the voluntary recall … to the voluntary recall of the MASCT System, which commenced in October 2013.
Total cost of revenue in 2013 was $345,519, consisting of $239,755 in costs related
POS AM
vfblh yi3mq
15 Apr 14
Prospectus update (post-effective amendment)
12:00am
8-K
EX-99.1
7e3hiovb
12 Aug 14
Atossa Genetics Announces Second Quarter 2014 Financial Results
12:00am
8-K
sm92rzqbmcf
4 Oct 13
Other Events
12:00am
POS AM
oqlrr4mtqnwv
18 Apr 14
Prospectus update (post-effective amendment)
12:00am
424B3
pcz5u0jo br
17 Dec 13
Prospectus supplement
12:00am
424B5
rw8l83o
27 Jan 14
Prospectus supplement for primary offering
12:00am
424B5
emhv68h192kh
23 Jan 14
Prospectus supplement for primary offering
12:00am